| Paroxysmal nocturnal hemoglobinuria: Where are we going |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Paroxysmal nocturnal hemoglobinuria: Where we stand |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Parsing the Paradox of Myelodysplastic Syndromes |
|
Journal of clinical oncology: official journal of the American Society Clinical Oncologysd |
Myelodysplastic Syndromes (MDS) |
| Pathogenesis of paroxysmal nocturnal hemoglobinuria |
|
Blood |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Patient and physician perceptions about blood transfusions in the myelodysplastic syndromes |
|
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
| Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria. |
|
PloS One |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Patient stratification in myelodysplastic syndromes: how a puzzle may become a map |
|
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
| Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studies |
|
Blood Advances |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies |
|
Annals of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
